Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Taiho Oncology, Inc.
ToLymph Inc.
George Washington University
Emory University
Eastern Cooperative Oncology Group
Boston Scientific Corporation
AstraZeneca
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
Shanghai Pulmonary Hospital, Shanghai, China
University of California, San Diego
Emory University
AstraZeneca
NRG Oncology
NATCO Pharma Ltd.
Revolution Medicines, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Yonsei University
Iovance Biotherapeutics, Inc.
Mayo Clinic
Cedars-Sinai Medical Center
University of Kentucky
M.D. Anderson Cancer Center
Thomas Jefferson University
Genelux Corporation
Institut Bergonié
Leiden University Medical Center
Fudan University
University of California, San Diego
GlaxoSmithKline
Verrica Pharmaceuticals Inc.
Situs Cancer Research Center
Sun Yat-sen University
Regeneron Pharmaceuticals